% 0期刊文章%萨拉歌% Gregg Fonarow %嵚盘%一个大和总研奥尔森%阿德里安·埃尔南德斯% Eric Peterson %马修Reeves %一个李Schwamm埃里克史密斯% % Jeffrey节省% T改善临床结果在急性缺血性中风医疗保险受益人得到的初始实现Guidelines-Stroke计划2003 - 2008 (S19.003) % D J神经病学2012% % P S19.003-S19.003 % V 78% N 1补充% X目的:研究观察临床中风的结果之前和之后医院软件质量计划的实施。首页背景21世纪的第一个十年变化在急性缺血性中风保健,包括更多地使用IV rt-PA和正式组织中风中心。从急性缺血性中风的临床结果的变化在这段时间内没有完全描述。设计/方法:我们分析了缺血性中风患者的临床结果的医院加入得到Guidelines-Stroke (GWTG-Stroke)从4月1日,2003年到2008年12月12日通过国家医疗保险数据集。我们指定三个时间段:pre (GWTG-Stroke参与前6个月),(GWTG-Stroke参与的前6个月),早期和晚期(GWTG-Stroke 6 - 18个月后实施)。分析结果包括出院回家;住院,30天,1年死亡率;30天,1年再入院治疗中风、心血管事件,所有的原因。结果:139293名患者从725年网站分析了平均年龄79.5岁,41%为男性,84%是白人。病人人口跨时间段是相似的。之间的显著变化和晚期阶段包括:减少30天死亡率(15.3%比13.0%,p <。)和1年(28.0%比25.5%,p <。),减少中风/ TIA再入院治疗30天(3.1%比2.4%,p <。)和1年(9.2%比8.7%,p < .002),降低了心血管事件再入院治疗30天(2.9%比2.3%,p <。)和1年(15.9%比13.5%,p <。),并降低所有原因再入院治疗30天(17.4%比15.1%,p <。)和1年(55.8%比53.0%,p <。)。结论:在前两年的参与,对医疗保险受益人急性缺血性中风的临床结果医院加入GWTG-Stroke大幅改善,30天死亡率低15%和24%降低中风或TIA的30天的住院率。 Further study is planned to determine if similar improvements in outcomes occurred at non-participating hospitals during this time frame.Disclosure: Dr. Song has nothing to disclose. Dr. Fonarow has received personal compensation for activities with UCLA, National Institutes of Health, Pfizer Inc, Medtronic, Inc., and Novartis. Dr. Fonarow has received royalty payments from UCLA. Dr. Fonarow has received research support from the National Institutes of Health. Dr. Pan has nothing to disclose. Dr. Olson has nothing to disclose. Dr. Hernandez has nothing to disclose. Dr. Peterson has received research support from Bristol Myers Squibb/Sanofi Aventis Partnership. Dr. Reeves has nothing to disclose. Dr. Smith has received personal compensation for activities with Genentech, Inc. as an advisory board member. Dr. Schwamm has received personal compensation for activities with CoAxia, Inc., Phreesia, RTI Health Solutions, and CryoCath as a medical advisory board member. Dr. Schwamm has received research support from Bristol-Myers Squibb-Sanofi. Dr. Saver has received personal compensation for activities with BrainsGate, CoAxia, ev3, Talecris, PhotoThera, and Sygnis. Dr. Saver has received research support from the NIH, ev3, and Concentric.Tuesday, April 24 2012, 15:00 pm-16:30 pm %U